SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Nielsen Elisabet I. 1973 )
 

Search: WFRF:(Nielsen Elisabet I. 1973 ) > (2020-2024) > Quantifying combine...

Quantifying combined effects of colistin and ciprofloxacin against Escherichia coli in an in silico pharmacokinetic-pharmacodynamic model

Zhao, Chenyan (author)
Uppsala universitet,Institutionen för farmaci
Kristoffersson, Anders N., 1985- (author)
Uppsala universitet,Institutionen för farmaci
Khan, David D. (author)
Uppsala universitet,Institutionen för farmaci
show more...
Lagerbäck, Pernilla (author)
Uppsala universitet,Infektionsmedicin
Lustig, Ulrika (author)
Uppsala universitet,Institutionen för medicinsk biokemi och mikrobiologi
Cao, Sha (author)
Uppsala universitet,Institutionen för medicinsk biokemi och mikrobiologi
Annerstedt, Charlotte (author)
Uppsala universitet,Institutionen för medicinska vetenskaper
Cars, Otto (author)
Uppsala universitet,Infektionsmedicin
Andersson, Dan I. (author)
Uppsala universitet,Institutionen för medicinsk biokemi och mikrobiologi
Hughes, Diarmaid, 1956- (author)
Uppsala universitet,Institutionen för medicinsk biokemi och mikrobiologi
Nielsen, Elisabet I., 1973- (author)
Uppsala universitet,Institutionen för farmaci
Friberg, Lena E. (author)
Uppsala universitet,Institutionen för farmaci
show less...
 (creator_code:org_t)
Springer Nature, 2024
2024
English.
In: Scientific Reports. - : Springer Nature. - 2045-2322. ; 14:1
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Co-administering a low dose of colistin (CST) with ciprofloxacin (CIP) may improve the antibacterial effect against resistant Escherichia coli, offering an acceptable benefit-risk balance. This study aimed to quantify the interaction between ciprofloxacin and colistin in an in silico pharmacokinetic-pharmacodynamic model from in vitro static time-kill experiments (using strains with minimum inhibitory concentrations, MICCIP 0.023–1 mg/L and MICCST 0.5–0.75 mg/L). It was also sought to demonstrate an approach of simulating concentrations at the site of infection with population pharmacokinetic and whole-body physiologically based pharmacokinetic models to explore the clinical value of the combination when facing more resistant strains (using extrapolated strains with lower susceptibility). The combined effect in the final model was described as the sum of individual drug effects with a change in drug potency: for ciprofloxacin, concentration at half maximum killing rate (EC50) in combination was 160% of the EC50 in monodrug experiments, while for colistin, the change in EC50 was strain-dependent from 54.1% to 119%. The benefit of co-administrating a lower-than-commonly-administrated colistin dose with ciprofloxacin in terms of drug effect in comparison to either monotherapy was predicted in simulated bloodstream infections and pyelonephritis. The study illustrates the value of pharmacokinetic-pharmacodynamic modelling and simulation in streamlining rational development of antibiotic combinations.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Farmaceutiska vetenskaper (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Pharmaceutical Sciences (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Infektionsmedicin (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Infectious Medicine (hsv//eng)

Keyword

Farmaceutisk vetenskap
Pharmaceutical Science

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view